A phase I, open-label, dose-escalation study of the novel oral proteasome inhibitor (PI) ONX 0912 in patients with advanced refractory or recurrent solid tumors.

被引：3
|
作者：
Papadopoulos, K. P.
Mendelson, D. S.
Tolcher, A. W.
Patnaik, A.
Burris, H. A.
Rasco, D. W.
Bendell, J. C.
Gordon, M. S.
Kato, G.
Wong, H.
Bomba, D.
Lee, S.
Gillenwater, H. H.
Woo, T.
Infante, J. R.
机构：
[1] South Texas Accelerated Res Therapeut START Ctr C, San Antonio, TX USA
[2] Pinnacle Oncol Hematol, Scottsdale, AZ USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Premiere Oncol, Santa Monica, CA USA
[5] Onyx Pharmaceut, Emeryville, CA USA
[6] Onyx Pharmaceut, Charlottesville, VA USA
[7] Sarah Cannon Canc Ctr, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.3075
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3075
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ONX 0912, a Novel Oral Proteasome Inhibitor (PI), In Patients (pts) With Advanced Refractory or Recurrent Solid Tumours: a Phase 1, Open-label, Dose Escalation Study
    Papadopoulos, K.
    Mendelson, D.
    Tolcher, A. W.
    Burris, H. A.
    Gordon, M.
    Wong, H.
    Bomba, D.
    Lee, S.
    Gillenwater, H.
    Infante, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S147 - S147
  • [2] Tolerability of split-dose oprozomib (ONX 0912) in patients with advanced refractory or recurrent solid tumors.
    Papadopoulos, Kyriakos P.
    Mendelson, David S.
    Tolcher, Anthony W.
    Burris, Howard A.
    Gordon, Michael S.
    Bomba, Darrin
    Gillenwater, Heidi H.
    Infante, Jeffrey R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors
    Minami, Hironobu
    Ando, Yuichi
    Ma, Brigette Buig Yue
    Lee, Jih-Hsiang
    Momota, Hiroyuki
    Fujiwara, Yutaka
    Li, Leung
    Fukino, Koichi
    Ito, Koji
    Tajima, Takeshi
    Mori, Asuka
    Lin, Chia-Chi
    [J]. CANCER SCIENCE, 2016, 107 (10) : 1477 - 1483
  • [4] Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.
    Ho, A. L.
    Bendell, J. C.
    Cleary, J. M.
    Schwartz, G. K.
    Burris, H. A.
    Oakes, P.
    Agbo, F.
    Barker, P. N.
    Senderowicz, A. M.
    Shapiro, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Frederik Marmé
    Carlos Gomez-Roca
    Kristina Graudenz
    Funan Huang
    John Lettieri
    Carol Peña
    Zuzana Jirakova Trnkova
    Jan Eucker
    [J]. Cancer Chemotherapy and Pharmacology, 2018, 81 : 727 - 737
  • [6] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Marme, Frederik
    Gomez-Roca, Carlos
    Graudenz, Kristina
    Huang, Funan
    Lettieri, John
    Pena, Carol
    Trnkova, Zuzana Jirakova
    Eucker, Jan
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 727 - 737
  • [7] A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors.
    Kristeleit, Rebecca Sophie
    Shapiro, Geoffrey
    LoRusso, Patricia
    Infante, Jeffrey R.
    Flynn, Michael
    Patel, Manish R.
    Tolaney, Sara M.
    Hilton, John Frederick
    Calvert, Alan Hilary
    Giordano, Heidi
    Isaacson, Jeffrey D.
    Borrow, Jennifer
    Allen, Andrew R.
    Jaw-Tsai, Sarah S.
    Burris, Howard A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
    Michael S. Gordon
    David S. Mendelson
    Mitchell Gross
    Martina Uttenreuther-Fischer
    Mahmoud Ould-Kaci
    Yihua Zhao
    Peter Stopfer
    David B. Agus
    [J]. Investigational New Drugs, 2013, 31 : 409 - 416
  • [9] A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
    Gordon, Michael S.
    Mendelson, David S.
    Gross, Mitchell
    Uttenreuther-Fischer, Martina
    Ould-Kaci, Mahmoud
    Zhao, Yihua
    Stopfer, Peter
    Agus, David B.
    [J]. INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 409 - 416
  • [10] Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
    Juric, Dejan
    Krop, Ian
    Ramanathan, Ramesh K.
    Wilson, Timothy R.
    Ware, Joseph A.
    Bohorquez, Sandra M. Sanabria
    Savage, Heidi M.
    Sampath, Deepak
    Salphati, Laurent
    Lin, Ray S.
    Jin, Huan
    Parmar, Hema
    Hsu, Jerry Y.
    Von Hoff, Daniel D.
    Baselga, Jose
    [J]. CANCER DISCOVERY, 2017, 7 (07) : 704 - 715
12345